Genomics applied to the treatment of breast cancer
Diaddin Hamdan, Thi Thuy Nga Nguyen, Christophe Leboeuf, Solveig Meles, Anne Janin, Guilhem Bousquet

To cite this version:
Diaddin Hamdan, Thi Thuy Nga Nguyen, Christophe Leboeuf, Solveig Meles, Anne Janin, et al.. Genomics applied to the treatment of breast cancer. Oncotarget, Impact journals, 2019, 10 (46), pp.4786-4801. 10.18632/oncotarget.27102 . inserm-02545178

HAL Id: inserm-02545178
https://www.hal.inserm.fr/inserm-02545178
Submitted on 16 Apr 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Genomics applied to the treatment of breast cancer

Diaddin Hamdan¹,², Thi Thuy Nguyen²,³,⁴, Christophe Leboeuf²,⁵, Solveig Meles², Anne Janin²,⁵,* and Guilhem Bousquet²,⁶,⁷,*

¹Hôpital La Porte Verte, Versailles F-78004, France
²U942, Université Paris-Diderot, INSERM, Paris F-75010, France
³National Cancer Hospital, Medical Oncology Department 2, Ha Noi 110000, Viet Nam
⁴Ha Noi Medical University, Oncology Department, Ha Noi 116001, Viet Nam
⁵AP-HP-Hôpital Saint-Louis, Laboratoire de Pathologie, Paris F-75010, France
⁶AP-HP-Hôpital Avicenne, Service d’Oncologie Médicale, Bobigny F-93000, France
⁷Université Paris 13, Leonard de Vinci, Villetaneuse F-93430, France

*Co-senior authors

Correspondence to: Guilhem Bousquet, email: guilhem.bousquet@aphp.fr

Keywords: constitutional genomics; genomics applied to treatment; genomics of breast cancer; molecular and histological classification; tumor heterogeneity

ABSTRACT

Breast cancer remains a major health issue in the world with 1.7 million new cases in 2012 worldwide. It is the second cause of death from cancer in western countries. Genomics have started to modify the treatment of breast cancer, and the developments should become more and more significant, especially in the present era of treatment personalization and with the implementation of new technologies. With molecular signatures, genomics enabled a de-escalation of chemotherapy and personalized treatments of localized forms of estrogen-dependent breast cancers. Genomics can also make a real contribution to constitutional genetics, so as to identify mutations in a panel of candidate genes. In this review, we will discuss the contributions of genomics applied to the treatment of breast cancer, whether already validated contributions or possible future applications linked to research data.

INTRODUCTION

Breast cancer is the first cancer in terms of incidence among women, with 1.7 million new cases in 2012 worldwide. It is also the second cause of death from cancer in western countries with 40,000 deaths per year [1, 2]. In the last 20 years, breast cancer mortality has continuously decreased as a result of mass screening programs and early diagnosis, but also as a consequence of improved treatment for both localized and metastatic disease [3, 4].

In the era of personalized cancer medicine, advances in genomics are essential assets. In this review, we will address current knowledge in genomics applied to the treatment of breast cancers.

HISTOLOGIC AND MOLECULAR CLASSIFICATIONS

There are schematically three main histologic types of breast cancer (Figure 1): i) estrogen-dependent breast cancers expressing the estradiol receptor (ER) and treated with a panel of drugs that target the estradiol receptor pathway [5]; ii) breast cancers overexpressing the human epidermal growth factor receptor 2 (HER2) oncoprotein and treated with anti-HER2-based chemotherapies, the first anti-HER2 being a therapeutic monoclonal antibody, trastuzumab [6]; and iii) “triple negative” breast cancers which lack the expression of the estradiol receptor, the progesterone receptor, and HER2. There are still no targeted therapies for triple-negative breast cancers, which
Breast Cancers

Histological classification

ER +
- Estradiol receptor expression
  - Anti-estradiol therapy

HER2 +
- HER2 overexpression
  - Anti-HER2 therapy

Triple negative
- ER - HER2 -
  - Chemotherapy

Molecular classifications and triple negative classification

ER +
- Luminal
  - Luminal A
  - Luminal B

HER2 +
- Molecular apocrine
  - Basal-like 1
  - Basal-like 2
  - Mesenchymal-like
  - Mesenchymal stem-like
  - Immunomodulatory

Triple negative
- Basal

Estradiol receptor expression
- Anti-estradiol therapy

HER2 overexpression
- Anti-HER2 therapy

Androgen receptor activation
- Anti-androgen therapy

EGFR expression
- Anti-EGFR therapy
- Taxanes

ADN repair pathways
- Cisplatin
- PARPP inhibitors

Figure 1: Breast cancers landscape evolution from histologic to molecular classifications.
have a high metastatic potential, and consequently a bad prognosis [7].

Since 2000, several molecular subtypes have been identified, including the aforementioned histological subtypes (Figure 1). Peru et al. identified six molecular sub-types: Luminal A, Luminal B, Luminal C, HER2-enriched, Basal-like and Normal-like [8–10]. The luminal A subtype has the best prognosis and the lowest proliferative potential, including highly estrogen-dependent breast cancers. Luminal B subtype is also estrogen-dependent, but to a lesser extent, and corresponds to a sub-group of more aggressive cancers with a higher proliferative potential [11]. For the basal-like subtype, 50 to 75% are triple-negative breast cancers. Their aggressiveness is frequently the result of the loss of the retinoblastoma protein 1 (pRb1), of a high rate of tumor protein 53 (TP53) gene mutations and also of mutations in genes involved in DNA-repair mechanisms, such as breast cancer type 1 susceptibility (BRCA1) gene [12].

This early molecular classification was later revised, with the following subtypes: Luminal A and B, HER2-positive/ER-positive, HER2-positive/ER-negative, basal p53-altered and basal p53-normal (Figure 1). In this more recent version, 7% of cancers are of unknown subtype because of the heterogeneous expression of markers [13, 14]. Since 2005, among ER-negative cancers, several teams have identified a “molecular apocrine” subtype, characterized by an activation of the androgen receptor (AR) pathway and by the expression of AR target genes in 50% of cases, or by HER2 overexpression [15–17]. In 2012, a new molecular classification was established which includes Luminal, molecular Apocrine and Basal-like subtypes (Figure 1) [18]. Different immunohistochemistry markers have been proposed for in situ characterization of molecular apocrine breast cancers, including androgen receptor (AR) and gross cystic disease fluid protein 15 (GCDFP15) [17].

In 2011, Lehman et al. proposed a molecular classification of triple-negative breast cancers which we will discuss later [19].

MOLECULAR SIGNATURES AND ESTROGEN-DEPENDENT BREAST CANCERS

For estrogen-dependent breast cancers, the contribution of genomics has been small. However, molecular signatures have substantially modified clinical practice, enabling the therapeutic decision for adjuvant chemotherapy to be redefined for localized breast cancers [20]. Three commercially available tests are currently used: MammaPrint® (Agilent, The Netherlands) [21, 22], OncotypeDx® [23] and PAM50 (Prediction of Microarray using 50 classifier genes plus 5 reference genes) (Prosigna® kit) (see Table 1) [24, 25]. These tests quantify the expression levels of a limited panel of genes in the primary tumor. Most of them were developed for formalin-fixed paraffin-embedded tissue samples for implementation in daily practice.

These molecular signatures are used to classify patients according to their risk of metastatic relapse, to guide the decision for adjuvant chemotherapy when conventional criteria are insufficient [20]. This is particularly true for ER-positive, HER2-negative breast cancers without lymph node involvement (N0): in this sub-group of patients, adjuvant chemotherapy significantly reduces the risk of metastatic relapse only for high-risk patients [26–28]. The OncotypeDx® signature comprises three risk categories, raising the question of how to treat «intermediate-risk» patients. Recently, the TAILORx study clearly demonstrated the absence of benefit from adjuvant chemotherapy in this subgroup of intermediate-risk patients [29]. A meta-analysis of 147 articles concluded that molecular signatures for breast cancer enable 10% of patients at high clinical risk of relapse to be reclassified as low-risk patients, thus reducing the use of chemotherapy, with a favorable cost-efficiency ratio and improved quality of life for non-treated patients [30].

For estrogen-dependent breast cancers, the other contributions of genomics remain in the research field. For example, recent studies have identified the presence of mutations of the estrogen receptor 1 (ESR1) gene, such as the D538G or Y537S/C/N mutations, associated with resistance to anti-estrogens. These mutations change the conformation of the ligand binding site, thereby reducing the affinity of tamoxifen for the estrogen receptor [31, 32]. The systematic screening for these mutations is not currently recommended. Further studies are required to demonstrate their possible usefulness in guiding hormone-therapy prescription in daily practice.

GENOMICS APPLIED TO THE TREATMENT OF HER2-OVEREXPRESSING BREAST CANCERS

It is recommended to determine HER2 status in the primary tumor or in metastatic samples using a standardized immunostaining method. For doubtful cases, in situ hybridization methods are currently used to determine the HER2 gene copy number [33, 34]. In 2013, an international consensus clearly defined the criteria for HER2 protein overexpression and for HER2 gene amplification [35].

However, these methods entail certain limitations, typically for micro-invasive foci in a primary tumor or a micro-metastatic axillary lymph node [36].

Digital droplet PCR (ddPCR), easier to implement than in situ hybridization methods, seems to be a reliable alternative for the evaluation of the HER2 copy number in breast or gastric cancers [37–39]. A major limitation could be intra-tumor heterogeneity. Indeed, primary breast cancers are heterogeneous [28], and this is also the case
for HER2 status [40]. Combining laser-microdissection with ddPCR overcomes this limitation, by enabling a precise assessment of the \( \text{HER2} \) copy number within a cancer sample. In a recent study, we validated the use of laser microdissection combined with ddPCR to assess \( \text{HER2} \) copy number in micro-invasive breast cancers with at least 50 invasive cancer cells. We then applied this methodology to a 45-year-old patient with extensive in situ breast cancer, and no associated micro-invasion except a micro-metastasis found only on one section of the sentinel axillary lymph node. We first laser-microdissected the micro-metastatic foci, and then used ddPCR to demonstrate that \( \text{HER2} \) was amplified. This led us to optimize the adjuvant treatment for our patient, and she received trastuzumab-based adjuvant chemotherapy [37].

For HER2-overexpressing breast cancers, another issue remains to be deciphered: is there any clinical benefit to be drawn from the systematic determination of \( \text{HER2} \) amplification level within the tumor? Singer \textit{et al.} demonstrated a correlation between the level of \( \text{HER2} \) amplification and the response to anti-HER2 treatments in the neoadjuvant setting [41]. Laser-microdissection of cancer cells from a metastatic tumor biopsy combined with ddPCR could be used to overcome signal dilution by enrichment with tumor cells. So, in a skin metastasis of a HER2-expressing breast cancer, we have demonstrated that \( \text{HER2} \) copy number evaluated by ddPCR passed from 6 to 34, without and with prior laser microdissection respectively (Figure 2).

**GENOMICS APPLIED TO THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCERS**

Triple-negative breast cancers remain a therapeutic challenge. Lehmann \textit{et al.} established a molecular classification with six molecular subtypes to personalize the treatment of these breast cancer sub-types: Basal-like 1 (BL1), Basal-like 2 (BL2), Immunomodulatory (IM), Mesenchymal-like (M), Mesenchymal stem-like (MSL), and Luminal androgen receptor (LAR) (Figure 1) [19]. In the neoadjuvant setting, Masuda \textit{et al.} demonstrated significant associations between these molecular subtypes and pathological complete response under chemotherapy. BL1 subtype is associated with greater chemo-sensitivity, whereas BL2 and LAR subtypes are more chemo-resistant subtypes [42].

### Table 1: Gene panel tests used for therapeutic decision of localized breast cancers (Adapted from [28])

| Signature                | Number of genes | Clinical application                                                                 |
|--------------------------|-----------------|--------------------------------------------------------------------------------------|
| MammaPrint               | 70              | N−, ER+ or ER− \( \text{Estimates relapse risk} \)                                  |
| OncotypeDX               | 21              | ER+, HER2−, N− \( \text{Estimates chemotherapy benefit and relapse risk during hormonotherapy} \) |
| EndoPredict              | 11              | ER+, HER2−, N− or N+ \( \text{Predicts local and metastatic relapse during hormonotherapy} \) |
| Prosigna (PAM50)         | 50              | ER+/N− and N+ treated by hormonotherapy \( \text{Predicts 10-year metastasis-free survival} \) |
| Breast Cancer Index      | 5 and 2 genes ratio | ER+, N− \( \text{Estimates metastatic risk} \) \( \text{Predicts late metastatic risk and efficacy of prolonged hormonotherapy} \) |
| Rotterdam                | 76              | ER+, N− \( \text{Predicts relapse under treatment with tamoxifen} \)                |
| BluePrint                | 80              | Discriminates sub-types with different level of sensitivity to adjuvant treatment |

N: Node status in TNM classification; ER: Estradiol Receptor; RT-PCR: Reverse Transcription-Polymerase Chain Reaction.
Unfortunately, this classification still has few clinical applications, even in clinical trials dedicated to triple-negative breast cancers. For example, the BL2 subtype, characterized by an activation of the epidermal growth factor pathway, could respond to anti-epidermal growth factor receptor (EGFR) therapies. A phase II study assessed the benefit of cetuximab, a monoclonal anti-EGFR antibody, in the treatment of 173 women with metastatic triple-negative breast cancers. The results were disappointing, with a non-significant survival gain of 2.2 months [43]. For anti-EGFR-based treatments, a study could be dedicated exclusively to BL2 subtypes, ideally with high \( EGFR \) copy numbers and a quadruple wild-type status of \( KRAS, NRAS, BRAF, \) and \( PIK3CA \) genes, as for colon cancers [43, 44].

The same arguments can be applied to the LAR subtype, characterized by androgen receptor signaling pathway activation, and corresponding to certain molecular apocrine sub-types [16]. The LAR subtype accounts for 11% of triple-negative breast cancers [19]. In two phase II studies using anti-androgens for the treatment of patients with metastatic triple-negative breast cancers, disease stabilization at 6 months was observed for less than 20% of patients [45, 46]. It should be noted that the patients were not pre-selected according to LAR subtype.

In 2012 and 2013, we conducted a pilot study among five women with metastatic triple-negative breast cancers. For the five patients, we performed transcriptomic analyses on metastasis biopsies, and classified their respective metastatic cancers according to Lehmann’s classification.

Figure 2: Laser-microdissection of cancer cells combined with ddPCR to precisely assess \( HER2 \) amplification level on a skin metastasis of recurrent \( HER2 \)-overexpressing breast cancer. (A) \( HER2 \) is typically overexpressed using immunohistochemistry (left panel). The right panel shows the laser-microdissected \( HER2 \)-overexpressing cancer cells. (B) the \( HER2 \) copy number is much higher in the laser-microdissected cells than in the whole tumor. MDA231 triple-negative breast cancer cell lines serve as a negative control while the BT474 \( HER2 \)-overexpressing cancer cell line serves as a positive control.
We also established individual xenograft models from the same metastasis biopsies. For each patient xenograft model, we tested a panel of drugs or drug combinations, guided by transcriptomic data. One patient was classified BL2, with EGF pathway activation and no mutation of the EGF pathway genes. In the corresponding xenograft, the most effective regimen was a combination of paclitaxel and cetuximab. This regimen was offered to the patient as a third-line resort treatment with almost complete metabolic response [47]. On the basis of transcriptomic analyses and chemosensitivity data obtained from the different xenografts, we personalized the resort treatment for the four other women in our study. In all cases, despite the fact that this resort treatment was third-line or fourth-line, the time-to-progression was longer than that observed with previous lines of treatment [48].

### GENOMICS AND TUMOR HETEROGENEITY

Tumor heterogeneity is probably insufficiently taken into account in daily clinical practice, particularly for the treatment of metastatic disease. Most molecular analyses are performed on primary tumors, even in metastatic stages. However, metastatic clones can be a minority in the primary tumors they are deriving from [49, 50]. For HER2 status assessment, we have previously noted the benefit of combining molecular and tissue analyses, particularly with the contribution of laser-microdissection to overcome the limitation of tumor heterogeneity [37–39, 51, 52].

Molecular analyses on metastases are rare, mainly because of difficulties in obtaining these samples, and despite the fact that radiology-guided biopsies have considerably reduced this limitation [53]. For breast cancer, eleven studies have been dedicated to whole-genome analyses of metastatic biopsies (Table 2). In addition, most of these studies only included small numbers of patients, and the genome analyses were generally performed on tumors that were not laser-microdissected. One large study included 216 metastatic samples, some of them paired with samples from the corresponding primary breast cancers. They showed that metastatic clones are enriched with certain molecular abnormalities compared to the primary tumors [54].

Our research team is conducting a program on brain metastases. As part of this program, we performed transcriptomic analyses on laser-microdissected metastatic lymph-nodes of 28 women with HER2-overexpressing or triple negative metastatic breast cancers. Supervised analyses compared the transcriptomic profiles of women who developed brain metastases with those who did not. We identified CDKN2A/p16 as a gene associated with the risk of brain metastases and decreased survival [55].

### GENOMICS AND CONSTITUTIONAL GENETICS OF BREAST CANCER

In the last ten years, a panel of genes has been proposed for the diagnosis of hereditary familial cancers. In the context of hereditary predisposition for breast and/or ovarian cancers, the United States National Comprehensive Cancer Network recommends a panel of nineteen genes and proposes corresponding clinical screening tests (Table 3) [56]. In France, the Genetics and Cancer Group, supported by the French National Cancer Institute, recently updated their recommendation to test a panel of 13 genes accompanied by prevention and screening measures for patients and their families (Tables 4 and 5) [57, 58]. With twenty-eight platforms covering the French territory and dedicated to molecular biology, patients at risk for hereditary cancer can have the benefit of recent technologies applied to constitutional genetics. These platforms have implemented high-throughput sequencing tools like the Next Generation Sequencing
Table 3: National Comprehensive Cancer Network guidelines for breast and ovarian cancer management based on genetic and familial high-risk assessment (Adapted from [56])

| Gene | Breast cancer risk management | Ovarian cancer risk management | Other cancer risk management |
|------|-------------------------------|-------------------------------|-----------------------------|
| **ATM** | Increased risk<br>Annual mammography and breast MRI starting at **40 years**<br>RRS: based on FH | Potential increase in risk with insufficient evidence to recommend RRS | Insufficient evidence for pancreas or prostate cancers |
| **BRCA1** | Increased risk<br>25–29 years, annual breast MRI or mammogram<br>30–75 years, annual mammogram and breast MRI<br>&gt;75 years, based on IR<br>RRS: based on IR and FH | Increased risk<br>RRS: based on individual risk and FH between **35-40 years** | Prostate, uterine (possible) |
| **BRCA2** | Increased risk<br>25–29 years, annual breast MRI or mammogram<br>30–75 years, annual mammogram and breast MRI<br>&gt;75 years, based on IR<br>RRS: based on IR and FH | Increased risk<br>RRS: based on IR and FH between **40-45 years** | Pancreas, prostate, melanoma |
| **PALB2** | Increased risk<br>Annual mammography and MRI starting at age **30 years**<br>RRS: based on FH | Insufficient evidence | Insufficient evidence |
| **TP53** | Increased risk<br>20–29 years, annual breast MRI or mammogram<br>30–75 years, annual breast MRI and mammogram<br>&gt;75 years, based on IR<br>RRS: based on IR and FH | No increased risk | Neurological cancers, colon, skin cancers |
| **CDH1** | Increased risk for lobular cancer<br>Annual mammogram and breast MRI starting at age **30 years**<br>RRS: based on FH | No increased risk | Diffuse gastric cancer |
| **PTEN** | Increased risk<br>Annual mammogram with breast MRI starting at age **30–35 years**<br>or 5-10 years before earliest breast cancer in family<br>&gt;75 years, based on IR<br>RRS: based on IR and FH | No increased risk | Endometrial cancer, thyroid, colon, renal cancer, skin cancers |
| **BRIP1** | Insufficient evidence | Increased risk<br>Consider RRS at **45–50 years** | Not available |
| **CHEK2** | Increased risk<br>Annual mammogram and breast MRI starting at age **40 years**<br>RRS: based on FH | No increased risk | Colon cancer |
### Table 4: Recommendations of the Cancer and Genetics Group and the French National Institute of Cancer concerning gene panel analyses in the context of a hereditary predisposition to breast and ovarian cancers (Adapted from [57])

| Gene   | Cytogenetic location | Penetrance | Protein functions                                                                 | Cumulate risk of breast cancer | References |
|--------|----------------------|------------|-----------------------------------------------------------------------------------|--------------------------------|------------|
| BRCA1  | 17q21.31             | High       | Repair of DNA double-strand breaks using homologous recombination, cell cycle control, maintaining of genome integrity | 46–87% lifetime risk          | [88, 89]   |
| BRCA2  | 13q13.1              | High       | Repair of DNA double-strand breaks using homologous recombination                 | 38–84% lifetime risk          | [88, 90]   |
| PALB2  | 16p12.2              | Moderate   | Partner of BRCA2 and regulator of its stability and its nuclear localization       | 35% at 70 years               | [91, 92]   |
| TP53   | 17p13.1              | High       | Transcription Factor, cellular cycle, apoptosis, senescence, DNA Repair           | 80% life-time risk (premenopausal) | [93, 94]   |
| CDH1   | 16q22.1              | Moderate   | E-cadherin, cellular adhesion molecule                                           | 39–52% before 40 years (lobular cancer) | [95, 96]   |
| PTEN   | 10q23.31             | High       | Tumor phosphatase suppressor inhibiting PI3K and MAPK pathways                   | 25–50% lifetime risk          | [97, 98]   |

MRI: Magnetic Resonance Imaging; RRS: Risk reduction surgery; FH: Family History; IR: Individual Risk.
| Gene   | Chromosome | Repair of DNA | Mismatch repair system | Telomere maintenance | BRCA1/2 function |
|--------|------------|---------------|------------------------|----------------------|------------------|
| RAD51C | 17q22      | Moderate      | Repair of DNA using homologous recombination | Not known            | [99–102]        |
| RAD51D | 17q12      | Moderate      | Repair of DNA using homologous recombination and maintaining of telomere | Not known            | [103–105]       |
| MLH1   | 3p22.2     | High          | Mismatch repair system | 5–18%                | [106–111]       |
| MSH2   | 2p21-p16   | Moderate      |                        |                      |                  |
| MSH6   | 2p16.3     | Moderate      |                        |                      |                  |
| PMS2   | 7p22.1     | Moderate      |                        |                      |                  |
| EPCAM  | 2p21       | Moderate      |                        |                      |                  |

Table 5: Screening or prevention recommendations for persons carrying mutations of genes analyzed in the Cancer and Genetics Group panel (Adapted from [58])

| Gene   | Breast surveillance | Risk reduction surgery | Gynecologic surveillance |
|--------|---------------------|------------------------|--------------------------|
|        |                     |                        |                          |
| BRCA1  |                      | Prophylactic mastectomy| Before RRS: standard surveillance and no efficacious ovarian screening available " | |
| BRCA2  | annual MRI + mammogram (± Ultrasound) | Prophylactic mastectomy (discussed from the age of 40 years and according to mutations and FH of OC) " | |
|        | After 65 years, mammogram (± Ultrasound) | | |
| PALB2  | (Recommendations HAS 2014 and INCa 2017") | Prophylactic mastectomy | | |
| CDH1   | (Recommendations HAS 2014 " and INCa 2017") | Prophylactic mastectomy | Standard surveillance | |
| PTEN   | No specific gynecological guidelines | | Standard surveillance of CD: MDC | |
| TP53   | Starting at 20 years, annual MRI + Ultrasound (no systematic mammogram) | If FH of OC: MDC | Standard surveillance | |
| RAD51C | No specific breast surveillance | Prophylactic annexectomy (discussed from the age of 45 years and according to FH of OC) | Before RRS: standard surveillance and no efficacious ovarian screening to be proposed " | |
| RAD51D | To be adapted to FH of BC according to guidelines HAS 2014" | | | |
| MLH1   | To be adapted to FH of BC according to guidelines HAS 2014" | Not indicated | Ovarian and/or uterine RRS | |
| MSH2   | To be discussed in MDC according to Lynch syndrome guidelines | | Uterine surveillance according to Lynch syndrome guidelines | |
| MSH6   | | | | |
| PMS2   | | | | |
| EPCAM  | | | | |

BC: Breast Cancers; OC: Ovarian Cancers; FH: Family History; CD: Cowden disease; MDC: Multidisciplinary Committee; RRS: Risk reduction surgery.

"Recommendation of French Health Authority (HAS) 2014: French Breast cancer National screening program.

"©Recommendation of French National Cancer Institute (INCa), April 2017.
(NGS) systems, to identify mutational hot-spots in a panel of high penetrance genes. Several types of NGS sequencers are currently used for routine care and also for research purposes, such as Illumina, Applied Biosystems SOLID System, 454 Life Sciences (Roche), Helicos HeliScope, Complete Genomics, Pacific Biosciences PacBio and Life Technologies Ion Torrent [59].

In sporadic breast cancers, NGS sequencing enables four subtypes to be discriminated on the basis of different genetic and epigenetic modifications, with three genes (PIK3CA, TP53, and GATA3) that are modified in more than 10% of patients. Basal-like breast cancers typically harbor mutations in the TP53, RB1, and BRCA1 genes, together with MYC amplifications [60].

Because of the potential therapeutic applications, the identification of inactivating mutations in the BRCA1 gene, a tumor suppressor gene, is important. BRCA1, because of its critical role in DNA repair mechanisms through homologous recombination, is one of the most important genes associated with hereditary breast cancer [61]. More than 75% of BRCA1-mutated breast cancers have a triple-negative phenotype and are classified as basal-like [8]. Constitutional BRCA1 mutations are of high penetrance, occur in 10% of breast cancer patients and in 20% of young women with triple-negative breast cancers [62]. BRCA1 sporadic mutations are also found in 1% of breast cancers, and the promoter can be hypermethylated in 11 to 14% of cases, resulting in BRCA1 gene inactivation [63–65].

A deficit in homologous recombination via BRCA1 inactivation has provided the rationale to concomitantly inhibit other DNA repair pathways, particularly the (ADP-ribose) polymerase (PARP) enzyme pathway. Olaparib, a PARP inhibitor, showed considerable benefit in patients with metastatic BRCA1-mutated breast cancers [66, 67]. We, therefore, need to look for BRCA1 germline mutations in patients at risk for hereditary breast cancer. For sporadic breast cancer, particularly for the triple negative sub-type, we also need to identify BRCA1-inactivating mutations in tumors.

In this domain of constitutional genetics, many questions remain unanswered, particularly the translational value of identifying mutations of unknown significance in genes of low to moderate penetrance. The contributions of Genome-Wide Association Studies (GWAS) have not been very great. To date, more than sixty GWAS have been conducted on breast cancer samples. A meta-analysis of these GWAS identified 84 loci of interest possibly associated with an increased risk of breast cancer [68, 69]. Numerous low penetrance variants have been identified, without validating their functional significance. One of these variants concerns the oncogene FGFR2, the FGFR2 protein being overexpressed in 5% of breast cancers. This variant corresponds to a single nucleotide polymorphism (SNP) that affects the binding site of FGFR2, thus activating the downstream signaling pathway in a ligand-independent manner [70]. It is necessary to address the potential benefit of targeting FGFR2 for therapeutic purpose. Another SNP, in the 8q24 region, participates in regulating MYC oncogene transcription which is distant from this SNP by more than 300 kb [71]. Most GWAS studies suggest that mutations in low penetrance genes could partially explain genetic predisposition to breast cancer, even though their functional significance remains unclear [72].

**CONCLUSIONS**

The contribution of genomics applied to the treatment of breast cancer remains moderate. In practice, it is limited to informing adjuvant treatment decisions for early-stage diseases and to HER2-overexpressing breast cancers whatever the stage. However, breast cancers are heterogeneous and complex. Treatments need to be adjusted according to molecular subtypes and guided by the underlying genetic events. Several programs are ongoing to map the complex genetics of breast cancer, using multi-omic approaches such as the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [73], which will help to take tumor heterogeneity into account more efficiently. Also, the increasingly widespread utilization of NGS will help to decipher the individual molecular complexity of breast cancers. This will rapidly increase the contribution of genomics in shaping breast cancer treatment in the next few years, especially in the present era of personalized treatments.

**Abbreviations**

ER: estradiol receptor; HER2: human epidermal growth factor receptor 2; Rb1: retinoblastoma protein 1; TP53: tumor protein 53 gene; BRCA1: breast cancer type 1 susceptibility gene; AR: androgen receptor; GCDFP15: gross cystic disease fluid protein 15; PAM50: Prediction of Microarray using 50 classifier genes plus 5 reference genes; ESR1: estrogen receptor 1 gene; ddPCR: digital droplet polymerase chain reaction; BL1: basal-like 1; BL2: basal-like 2; IM: immunomodulatory; M: mesenchymal-like; MSL: mesenchymal stem-like; LAR: luminal androgen receptor; EGFR: epidermal growth factor receptor; NGS: next generation sequencing; PARP: ADP-ribose polymerase; GWAS: genome-wide association studies; SNP: single nucleotide polymorphism; METABRIC: Molecular Taxonomy of Breast Cancer International Consortium; N: nodes; TNM: tumor, node, metastases; RT-PCR: Reverse Transcription-Polymerase Chain Reaction; MRI: Magnetic Resonance Imaging; RRS: Risk reduction surgery; FH: Family History; IR: Individual Risk; BC: Breast Cancers; OC: Ovarian Cancers; CD: Cowden disease; MDC: Multidisciplinary Committee; HAS: French Health Authority; INCa: French National Cancer Institute.
Author contributions

The following made substantial contributions to conception and design of the paper: Hamdan D, Janin A, and Bousquet G; performed revision and corrections: Leboeuf C, Nguyen TT and Meles S.

ACKNOWLEDGMENTS

We would like to thank Mrs. A. Swaine for revising the English language.

CONFLICTS OF INTEREST

No authors have any conflicts of interest to report.

FUNDING

None.

REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136:E359–86. https://doi.org/10.1002/ijc.29210. [PubMed]
2. Tang Y, Wang Y, Kiani MF, Wang B. Classification, Treatment Strategy, and Associated Drug Resistance in Breast Cancer. Clin Breast Cancer. 2016; 16:335–43. https://doi.org/10.1016/j.clbc.2016.05.012. [PubMed]
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29. https://doi.org/10.3322/caac.21254. [PubMed]
4. Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985-2016. Breast. 2017; 31:46–50. https://doi.org/10.1016/j.breast.2016.10.005. [PubMed]
5. Osborne CK, SchifR. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011; 62:233–47. https://doi.org/10.1146/annurev-med-070909-182917. [PubMed]
6. Higgin MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest. 2011; 121:3797–803. https://doi.org/10.1172/JCI157152. [PubMed]
7. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363:1938–48. https://doi.org/10.1056/NEJMra1001389. [PubMed]
8. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, et al. Molecular portraits of human breast tumours. Nature. 2000; 406:747–52. https://doi.org/10.1038/35021093. [PubMed]
9. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98:10869–74. https://doi.org/10.1073/pnas.191367098. [PubMed]
10. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100:8418–23. https://doi.org/10.1073/pnas.0932692100. [PubMed]
11. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ, Albain KS, André F, Bergh J, Bonnfoi H, Bretel-Morales D, Burstein H, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013; 24:2206–23. https://doi.org/10.1093/annonc/mdt303. [PubMed]
12. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011; 16:61–70. https://doi.org/10.1634/theoncologist.2011-S1-61. [PubMed]
13. Green AR, Powe DG, Rakha EA, Soria D, Lemetre C, Nolan CC, Barros FF, Macmillan RD, Garibaldi JM, Ball GR, Ellis IO. Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers. Br J Cancer. 2013; 109:1886–94. https://doi.org/10.1038/bjc.2013.528. [PubMed]
14. Rakha EA, Soria D, Green AR, Lemetre C, Powe DG, Nolan CC, Garibaldi JM, Ball G, Ellis IO. Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer. Br J Cancer. 2014; 110:1688–97. https://doi.org/10.1038/bjc.2014.120. [PubMed]
15. McNamara KM, Moore NL, Hickey TE, Sasano H, Tilley WD. Complexities of androgen receptor signalling in breast cancer. Endocr Relat Cancer. 2014; 21:T161–81. https://doi.org/10.1530/ERC-14-0243. [PubMed]
16. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, Macrogan G, Bergh J, Cameron D, Goldstein D, Duss S, Nicoulaz AL, Brisken C, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24:4660–71. https://doi.org/10.1038/sj.onc.1208561. [PubMed]
17. Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellerah L, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Boursyn E, de Cremoux P, de Bazelaire C, Albiter M, et al. Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15. Breast Cancer Res. 2013; 15:R37. https://doi.org/10.1186/bcr3421. [PubMed]
18. Guédj M, Marisa L, de Reynies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Berthaeau P, Bertrand F, Bonnet F, et al. A refined molecular taxonomy of breast cancer. Oncogene. 2012; 31:1196–206. https://doi.org/10.1038/ onc.2011.301. [PubMed]
tumors maintained in distant metastases. Proc Natl Acad Sci U S A. 2003; 100:15901–05. https://doi.org/10.1073/pnas.2634067100. [PubMed]

79. Wang C, Iakolive VV, Wong V, Leung S, Warren K, Iakoliveva G, Arneson NC, Pintilliie M, Miller N, Youngson B, McCreary DR, Done SJ. Genomic alterations in primary breast cancers compared with their sentinel and more distal lymph node metastases: an aCGH study. Genes Chromosomes Cancer. 2009; 48:1091–101. https://doi.org/10.1002/gcc.20711. [PubMed]

80. Desouki MM, Liao S, Huang H, Conroy J, Nowak NJ, Shepherd L, Gaile DP, Geradts J. Identification of metastasis-associated breast cancer genes using a high-resolution whole genome profiling approach. J Cancer Res Clin Oncol. 2011; 137:795–809. https://doi.org/10.1007/s00432-010-0937-1. [PubMed]

81. Craig DW, O’Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JJ, Aitelli CL, Osborne CR, Izatt T, et al. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther. 2013; 12:104–16. https://doi.org/10.1158/1555-7167.MCT-12-0781. [PubMed]

82. Lee JY, Park K, Lim SH, Kim HS, Yoo KH, Jung KS, Song HN, Hong M, Do IG, Ahn T, Lee SK, Bae SY, Kim SW, et al. Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer. Oncotarget. 2015; 6:43731–42. https://doi.org/10.18632/oncotarget.6192. [PubMed]

83. Onstenk W, Siewuerts AM, Weekhout M, Mostert B, Reijm EA, van Deurzen CH, Bolt-de Vries JB, Peeters DJ, Hamberg P, Seynaeve C, Jager A, de Jongh FE, Smid M, et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Lett. 2015; 362:36–44. https://doi.org/10.1016/j.canlet.2015.03.020. [PubMed]

84. McBryant J, Fagan A, McCartan D, Bane FT, Varelija D, Cocciglia S, Byrne C, Bolger J, Mellow M, Hudson L, Tibbitts P, Gaora PQ, Hill AD, Young LS. Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clin Cancer Res. 2015; 21:5371–79. https://doi.org/10.1158/1078-0432.CCR-14-2155. [PubMed]

85. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyew N, Haq CM, Crothers JR, Easerman LJ, Tripathy D, van ’t Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015; 149:121–31. https://doi.org/10.1007/s10549-014-3215-0. [PubMed]

86. Kimbung S, Johannson I, Danielsson A, Veeër S, Egyhazi Brage S, Frostvik Stolt M, Skoog L, Carlsson L, Einbeigi Z, Lidbrink E, Linderholm B, Loman N, Malmström PO, et al. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer. Clin Cancer Res. 2016; 22:146–57. https://doi.org/10.1158/1078-0432.CCR-15-0487. [PubMed]
102. Thompson ER, Boyle SE, Johnson J, Ryland GL, Sawyer S, Choong DY, ConFab K, Chenevix-Trench G, Trainer AH, Lindeman GJ, Mitchell G, James PA, Campbell IG. Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat. 2012; 33:95–99. https://doi.org/10.1002/humu.21625. [PubMed]

103. Pelttari LM, Kiiski JI, Ranta S, Vilske S, Blomqvist C, Aittomäki K, Nevanlinna H. RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. Springerplus. 2015; 4:92. https://doi.org/10.1186/s40064-015-0880-3. [PubMed]

104. Kleibl Z, Kristensen VN. Women at high risk of breast cancer: molecular characteristics, clinical presentation and management. Breast. 2016; 28:136–44. https://doi.org/10.1016/j.breast.2016.05.006. [PubMed]

105. Online Mendelian Inheritance in Man OJHU, Baltimore, MD. MIM Number: *602954: 12/04/2013.

106. Kohlmann W, Gruber SB. Lynch Syndrome. In: Adam MP (ed.), Ardinger HH (ed.), Pagon RA (ed.), Wallace SE (ed.), Bean LJ (ed.), Stephens K (ed.), Amemiya A (ed.), editors. GeneReviews((R)). (Seattle (WA)); 1993.

107. Online Mendelian Inheritance in Man OJHU, Baltimore, MD. MIM Number: *120436 : 04/20/2018.

108. Online Mendelian Inheritance in Man OJHU, Baltimore, MD. MIM Number: *609309 : 10/05/2016.

109. Online Mendelian Inheritance in Man OJHU, Baltimore, MD. MIM Number: *600678: 01/24/2018.

110. Online Mendelian Inheritance in Man OJHU, Baltimore, MD. MIM Number: *600259: 12/27/2016.

111. Online Mendelian Inheritance in Man OJHU, Baltimore, MD. MIM Number: *185535: 12/18/2017.